Network Pharmacology, Molecular Docking and in vivo-based Analysis on the Effects of the MBZM-N-IBT for Arthritis.

Autor:	Moharana AK; Drug Development and Analysis Lab, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, 751029, India., Gaur M; Drug Development and Analysis Lab, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, 751029, India., Kumar Mohapatra T; Siksha O Anusandhan University Pharmaceutical Sciences Bhubaneswar India.; Nityananada College of Pharmacy, Sergarh, Balasore, Odisha, 756060, India., Dash RN; Drug Development and Analysis Lab, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, 751029, India., Subudhi BB; Drug Development and Analysis Lab, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, 751029, India.
Jazyk:	angličtina
Zdroj:	Current computer-aided drug design [Curr Comput Aided Drug Des] 2024 Aug 06. Date of Electronic Publication: 2024 Aug 06.
DOI:	10.2174/0115734099307360240731052835
Abstrakt:	Introduction: Arthritis is the cause of morbidity associated with Chikungunya virus (CHIKV) infection. It persists even after the virus has been cleared from the body. MBZM-NIBT was earlier shown to inhibit (CHIKV) infection in vitro and in vivo. Objective: The objective of this study is to determine the ability of MBZM-N-IBT to manage arthritis independent of CHIKV infection. Method: The acute toxicity of MBZM-N-IBT was determined to find a permissible oral dose. Effects against inflammation and arthritis were determined in relevant preclinical models. Network pharmacology was used to propose possible modes of action. Result: It showed no acute toxicity orally, with an estimated LD50 of more than 5000 mg/kg in rats. It significantly reduced inflammation. Its effect against Complete Freund's Adjuvant (CFA) induced arthritis was comparable to that of Diclofenac sodium. Network pharmacology analysis revealed that MBZM-N-IBT can potentially interfere with multiple targets and pathways. MMP12 and CTSD were found to be the most probable hub targets of MBZM-N-IBT for its effect against arthritis. Conclusion: In conclusion, MBZM-N-IBT is safe at 50 mg/kg and can manage arthritis independent of CHIKV infection through modulation of multiple pathways and arthritis-associated targets. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu